araag2/HINT huggingface dataset:
Clinical trial NCT00568685 (phase 3, status: completed)
Conditions: attention deficit hyperactivity disorder
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: atomoxetine hydrochloride, atomoxetine hydrochloride, atomoxetine hydrochloride
SMILES: CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1, CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1, CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients will be outpatients who are aged 6 to 18 years old at the initial screening
             visit.

          -  Patients must have ADHD, based on the accepted criteria for that disease

          -  Patients must not have taken any medication used to treat ADHD for at least two weeks
             prior to beginning study treatment; and at least one week prior to the study screening
             visit during which initial ADHD assessments were made

          -  Patients must be able to swallow capsules

          -  Patients and parents (or legal guardians) must be judged by the study investigator to
             be reliable to keep appointments for clinic visits and all tests, including blood
             tests and any other required examinations

        Exclusion Criteria:

          -  Patients must not have received any treatment within the last 30 days with a drug that
             has not been approved by their country's appropriate government agency

          -  Patients will not be included in the study if they have previously experienced any
             unwanted effects or serious medical events during atomoxetine treatment

          -  Patients will not be included in the study if they are judged by the study
             investigator to be at serious suicidal risk

          -  Patients will not be included in the study if they have cardiovascular disease or
             other conditions that could be worsened by an increased heart rate or increased blood
             pressure
Clinical trial NCT00221845 (phase 3, status: completed)
Conditions: children, chronic renal failure, hypertension, acquired kidney disease, congenital kidney disease
ICD codes: Y93.6A, Y92.110, Y92.111, Y92.112, Y92.113, Y92.114, Y92.115, I13.11, I13.2, I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: ace inhibition, intensified blood pressure control, add-on angiotensin receptor blockade
SMILES: [H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC, CC1=CC(O)=CC(C)=C1Cl, CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age 3-18 years

          -  Moderate state of renal failure (creatinine clearance 15 - 75 ml / min / 1.73 m²)

          -  Mean arterial blood pressure (ABPM) > 50.percentile and/or antihypertensive treatment

          -  Written informed consent

        Exclusion Criteria:

          -  Age <3 years or >18 years at start of study

          -  Unstable clinical condition (vomiting, anorexia, etc) or superimposed important
             disease

          -  Unilateral or bilateral renal artery stenosis

          -  Urological surgery possibly affecting renal function expected during study period

          -  Insufficient compliance with prescribed antihypertensive medication during the run-in
             period

          -  Secondary renal diseases such as lupus, amyloidosis and primary hyperoxaluria, and
             patients treated with immunosuppressive agents (including corticosteroids)

          -  Severe primary cardiac disease, hepatic insufficiency and malabsorption syndrome

          -  Erythropoietin or growth hormone therapy with a duration of less than 3 months prior
             to run-in period

          -  Pregnancy
Clinical trial NCT00089856 (phase 3, status: terminated)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: chemotherapy (taxotere and prednisone)
SMILES: [H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1
Reason stopped: 
    based on futility analysis showing <30% chance of meeting primary endpoint.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed diagnosis of or clinical history consistent with adenocarcinoma of the
             prostate

          -  Metastatic prostate cancer deemed to be unresponsive or refractory to hormone therapy

          -  Detectable metastases

          -  Any Gleason score

          -  ECOG performance status 0-2

        Exclusion Criteria:

          -  Prior treatment with chemotherapy

          -  Prior Immunotherapy

          -  Prior treatment with gene therapy

          -  Significant cancer related pain
Clinical trial NCT00206089 (phase 3, status: terminated)
Conditions: thromboembolism
ICD codes: O88.22, O88.23, O88.211, O88.212, O88.213, O88.219
Drugs: exanta
SMILES: CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(C=C1)C(\N)=N\O)C1CCCCC1
Reason stopped: 
    melagatran/ximelagatran was withdrawn from the market and clinical development in february 2006
    in the interest of patient safety.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Signed informed consent,

          -  Female or male aged 18 years and over

          -  Patient scheduled for primary elective hip replacement or patient requiring surgery
             for hip fracture.

        Exclusion Criteria:

          -  History of heparin-induced thrombocytopenia

          -  Conditions associated with increased risk of bleeding, renal impairment, known active
             liver disease or liver insufficiency.

          -  Myocardial infarction, Ischemic stroke or Transient Ischemic Attack (TIA), systemic
             embolism or venous thrombo-embolism within 30 days of enrollment.
Clinical trial NCT00163137 (phase 3, status: completed)
Conditions: osteoporosis
ICD codes: M81.6, Z82.62, Z13.820, M81.8, Z87.310, M81.0, M80.80XS
Drugs: lasofoxifene, raloxifene, placebo
SMILES: [H][C@@]1(CCC2=CC(O)=CC=C2[C@@]1([H])C1=CC=C(OCCN2CCCC2)C=C1)C1=CC=CC=C1, CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Postmenopausal women with low bone density (osteopenia) and screening labs, pelvic
             ultrasound, mammogram without significant findings

        Exclusion Criteria:

          -  Presence of metabolic bone disease, fractures, blood clots, or recent cancer.

          -  Any use of selective estrogen receptor modulators, investigational drugs, or recent
             use of osteoporosis treatments, certain hormones, or medication for blood clots or
             seizures.
Clinical trial NCT00250965 (phase 3, status: terminated)
Conditions: coronary artery disease, valvular heart disease
ICD codes: I25.10, I25.110, I25.119, I25.111, I25.118
Drugs: intravenous magnesium
SMILES: [Mg++]
Reason stopped: 
    terminated by dsmb; futility analysis showing mg treatment not efficacious
  
Eligibility criteria:

        Inclusion Criteria:

          -  patient undergoing coronary artery bypass surgery with or without valve procedure

          -  scheduled for on-pump or cardiopulmonary bypass protocol

        Exclusion Criteria:

          -  existing atrial fibrillation/flutter in the past year or on antiarrhythmic medications

          -  ventricular fibrillation

          -  sustained ventricular tachycardia

          -  2nd or 3rd degree heart block

          -  paroxysmal supraventricular tachycardia

          -  major aortic repair planned during open-heart procedure

          -  permanent atrial/ventricular pacemaker implanted

          -  dialysis dependent or creatinine clearance < 35 umoles/min or oliguric/anuric renal
             failure

          -  patient intolerant of beta blockers

          -  patient has reactive airways disease dependent on regular beta-adrenergic agents

          -  patient is scheduled to undergo off-pump surgical protocol
Clinical trial NCT00003912 (phase 3, status: completed)
Conditions: liver cancer
ICD codes: D13.4, Z85.05, C22.8, C78.7, C22.9, D37.6
Drugs: carboplatin, cisplatin, doxorubicin hydrochloride
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically proven hepatoblastoma or hepatocellular carcinoma

               -  Diagnostic surgical biopsy strongly recommended for all patients and mandatory
                  for the following:

                    -  Children under 6 months of age

                    -  Children over 3 years of age

                    -  Patients with a normal serum alfa-fetoprotein (alfa-FP)

               -  Compatible imaging and raised serum alfa-FP level mandatory if no biopsy
                  performed

          -  Standard risk disease:

               -  Tumors involving no more than 3 hepatic sections

               -  No extrahepatic abdominal disease

               -  No metastases

          -  High risk disease:

               -  Tumors involving all 4 hepatic sections AND/OR

               -  Evidence of extrahepatic metastases or abdominal disease

          -  Presence or absence of metastatic disease must be documented by chest x-ray and/or
             lung CT scan

        PATIENT CHARACTERISTICS:

        Age:

          -  16 and under at diagnosis

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Not specified

        Renal:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  Not specified

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  Not specified

        Surgery:

          -  See Disease Characteristics

          -  Prior surgery allowed
Clinical trial NCT00578695 (phase 3, status: completed)
Conditions: hyponatremia
ICD codes: P74.22, E87.1
Drugs: lixivaptan, placebo
SMILES: CC1=CC=C(F)C=C1C(=O)NC1=CC=C(C(=O)N2CC3=CC=CN3CC3=C2C=CC=C3)C(Cl)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female patients 18 years of age or older with hyponatremia and hospitalized
             for congestive heart failure.
Clinical trial NCT00549757 (phase 3, status: terminated)
Conditions: type 2 diabetes mellitus, cardiovascular disease
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44, A52.00, A52.09, A50.54, Z01.810, Q87.418, Z13.6, R94.30
Drugs: aliskiren, placebo
SMILES: CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    lack of benefit and safety concern
  
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes and at least one of the following:

               -  Macroalbuminuria and an eGFR ≥30 mL/min/1.73 m2

               -  Microalbuminuria and a reduced kidney function (eGFR eGFR ≥30 and <60 mL/min/1.73
                  m2)

               -  A history of CV disease (previous MI, previous stroke, heart failure, coronary
                  artery disease, history of percutaneous coronary intervention, angiography proven
                  stenosis ≥50% in at least one coronary artery and a reduced kidney function (eGFR
                  ≥30 and <60 mL/min/1.73 m2)

          -  Concomitant treatment should follow national guidelines and must include either an
             Angiotensin-converting-enzyme-inhibitor (ACEi) or an Angiotensin-receptor-blocker
             (ARB) but not both.

        Exclusion Criteria:

          -  Type 1 diabetes mellitus

          -  Cardiovascular event or procedure ≤ 3 months prior to Visit 1

          -  Unstable serum creatinine

          -  Hypertension: Mean sitting systolic blood pressure (msSBP) ≥ 135 and < 170 mmHg or
             Mean sitting diastolic blood pressure (msDBP) ≥ 85 and < 110 mmHg unless treated with
             at least 3 anti-hypertensive medications

          -  Hypertension msSBP ≥ 170 or msDBP ≥ 110 mmHg

          -  Baseline Serum Potassium > 5.0 mmol/L

          -  Patients who are treated with two renin-angiotensin-aldosterone-system-blockers

          -  Patients with NYHA class III or IV heart failure

          -  Known renal artery stenosis

          -  Previous randomization into the AVOID trial (CSPP100C2201)

        EXCLUSION SPECIFIC TO THE SAFETY FOLLOW-UP PERIOD:

        - Aliskiren or aliskiren containing fixed combination products must not be used

        Other protocol-defined inclusion/exclusion criteria applied
Clinical trial NCT00658736 (phase 3, status: completed)
Conditions: chronic pancreatitis
ICD codes: K86.1, K86.0
Drugs: triamcinolone, bupivicaine alone
SMILES: [H]\C(=C(\[H])C1=CC=C(OC)C=C1)C(=O)OCC(CC)CCCC, CNC[C@H](O)C1=CC(O)=C(O)C=C1
Eligibility criteria:

        Inclusion criteria include:

          -  Age >18 yrs

          -  Ability for informed consent

          -  Chronic pancreatic-type abdominal pain (type B) (11).

        Exclusion criteria include:

          -  Pregnancy

          -  Malignancy

          -  Recent acute pancreatitis (within 2 months)

          -  Elevated INR (>1.5) or low platelet count (<75 cells/mm3)

          -  Allergy to eggs or "caine" anesthetics or corticosteroids; AND

          -  Becks depression score>20.
Clinical trial NCT00627445 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: biphasic insulin aspart 30, metformin, biphasic insulin aspart 50
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, CSCC[C@H](N)C(O)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes

          -  Currently treated with premix human insulin twice daily with or without oral
             antidiabetic drugs for at least 3 months

          -  HbA1c (Glycosylated Haemoglobin A1c) between 7.5% - 12.0% (both inclusive)

          -  FPG (Fasting Plasma Glucose) higher than 7.0 mmol/L

          -  BMI (Body Mass Index) 23-40 kg/sq.m (both inclusive)

        Exclusion Criteria:

          -  Metformin contraindications according to local practice

          -  Systemic use of TZDs (thiazolidinediones) for more than 1 month within 6 months prior
             to this trial
Clinical trial NCT00643851 (phase 3, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: dapagliflozin, metformin xr
SMILES: CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Males & females, 18-77 years old inclusive, with type 2 diabetes and with inadequate
             glycemic control

          -  Drug naive or treated with anti-diabetic medication for < 24 weeks since original
             diagnosis

          -  C-peptide ≥ 1.0 ng/mL

          -  Body Mass Index ≤ 45.0 kg/m

          -  Serum creatinine < 1.50 mg/dL for men or < 1.40 mg/dL for women

        Exclusion Criteria:

          -  AST and/or ALT >3.0 times the upper limit of normal (ULN)

          -  Serum total bilirubin > 2.0 mg/dL

          -  Creatine kinase > 3X the upper limit of normal (ULN)

          -  Symptoms of severely uncontrolled diabetes

          -  Currently unstable or serious cardiovascular, renal, hepatic, hematological,
             oncological, endocrine, psychiatric or rheumatic diseases
Clinical trial NCT00551616 (phase 3, status: completed)
Conditions: contraception
ICD codes: Z92.0, Z30.012, Z30.09
Drugs: cdb-2914, levonorgestrel
SMILES: CN(C)C1=CC=C(C=C1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12, [H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]
Eligibility criteria:

        Inclusion Criteria:

          -  women 16 or older in UK(except Northern Ireland) sites, 17 years or more in Northern
             Ireland (UK) and 18 years or more in Ireland and US

          -  present within 120 hours of unprotected intercourse

          -  regular menstrual cycles

          -  No current use of hormonal contraception

          -  Willing to not use hormonal methods of contraception until study completion

          -  At least one complete menstrual cycle (2 menses) post miscarriage, delivery or
             abortion

          -  For women who present more than 72 hours after intercourse, decline the insertion of
             an IUD for emergency contraception

          -  Able to provide informed consent

          -  Willing to abstain from further acts of unprotected intercourse until study completion

        Exclusion Criteria:

          -  One or more acts of unprotected intercourse more than 120 hours

          -  current or recent use of hormonal methods of contraception

          -  currently pregnant or breastfeeding

          -  tubal ligation or current use of IUD

          -  Use of hormonal emergency contraception since last menstrual period

          -  Current use of IUD

          -  Tubal ligation

          -  Partner with a vasectomy

          -  Unsure about the date of the last menstrual period

          -  Severe asthma insufficiently controlled by oral glucocorticoid

          -  Hypersensitivity to the active substance levonorgestrel or any of the excipients of
             the drug products used in the study
Clinical trial NCT00655551 (phase 3, status: completed)
Conditions: partial epilepsies, partial onset seizures
ICD codes: G40.011, G40.019, G40.001, G40.009
Drugs: lacosamide, lacosamide, lacosamide
SMILES: COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1, COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1, COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of epilepsy with simple partial seizures and/or complex partial seizures

          -  Stable dose regimen of 1 to 2 marketed antiepileptic drug(s) (AED(s)) for 28 days
             prior to screening and duration of trial

          -  Acceptable candidate for venipuncture and intravenous (iv) infusion

          -  At least 1 partial seizure with motor component per 90 days

          -  Maximum allowed seizure frequency during 28 days prior to screening is 40 partial
             seizures of any type

        Exclusion Criteria:

          -  Previous use of lacosamide

          -  History of primary generalized seizures

          -  History of status epilepticus within last 12 months

          -  History of cluster seizures during 8 week period prior to screening

          -  Non-epileptic events, including psychogenic seizures that could be confused with
             seizures

          -  Use of neuroleptics, monoamine oxidase (MAO) inhibitors, barbiturates, or narcotic
             analgesics within 28 days prior to screening

          -  Received any rescue benzodiazepines more than once during the 28 days prior to
             screening

          -  Concomitant treatment of felbamate or previous felbamate therapy within last 6 months

          -  Prior or concomitant vigabatrin use
Clinical trial NCT01136954 (phase 3, status: completed)
Conditions: partial seizures
ICD codes: G40.111, G40.119, G40.211, G40.219, G40.101, G40.109, G40.201
Drugs: zonisamide
SMILES: NS(=O)(=O)CC1=NOC2=CC=CC=C12
Eligibility criteria:

        INCLUSION CRITERIA:

          1. Subject has completed the double-blind study E2090-E044-312.

          2. Parent/caregiver is willing to sign an informed consent where the subject is under the
             age of consent.

          3. Subject is male or female aged 6 to 18 years who is willing to give informed (written
             or verbal) assent, if applicable. If mandated by local regulations, subjects of
             relevant age will be required to sign an appropriate informed consent.

          4. Subject is in general good health as determined by medical history, physical exam and
             screening laboratory results.

        EXCLUSION CRITERIA:

          1. Subject has a body weight < 20 kg.

          2. Subject has developed a history of renal calculi or renal insufficiency (creatinine
             level > 135 µmol/l (1.5 mg/dl).

          3. Subject has a known diagnosis of human immunodeficiency virus (HIV) or hepatitis B or
             C.

          4. Subject has a history of sensitivity to sulfonamide drugs or zonisamide and its
             excipients.

          5. Female subject of 10 years of age or greater, or of child bearing potential (i.e.
             started menses) and is not taking or prepared to take a medically acceptable form of
             contraception (i.e. oral contraceptive pill, surgical sterilization, an implant or
             injected form of contraception, or intrauterine device), or who is not prepared to
             abstain from sexual activity for the duration of the study and for one month after the
             last administration of study medication. NOTE: Should a female subject become of child
             bearing potential during the study, they must be reconsented in order to given consent
             to undergo pregnancy testing and either confirm abstinence or receive a medically
             appropriate form of contraception.

          6. Subject has a recent history of excessive alcohol use or drug abuse.

          7. Subject has a history of suicide attempt.

          8. Subject has a clinically significant organic disease.

          9. Subject has a history of demonstrated non-compliance with treatment or subject or
             parent/legal guardian can be reasonably expected not to be compliant with study
             procedures or to complete the study.

         10. Frequent need of rescue benzodiazepines (one or more times a month).

         11. Concomitant use of acetazolamide, carbonic anhydrase inhibitors such as topiramate,
             furosemide and drugs with anticholinergic activity.

         12. Concomitant use of felbamate or use of felbamate within 2 months prior to Visit 1 of
             the E2090-E044-312 study.
Clinical trial NCT00633932 (phase 3, status: completed)
Conditions: reflux esophagitis
ICD codes: K21.9, K21.00, K21.01
Drugs: esomeprazole, esomeprazole, omeprazole
SMILES: COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1, COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1, [Na+].OC([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Endoscopically verified Reflux Esophagitis classified into Los Angeles classification
             Grade A, B, C or D within 1 week before randomisation

        Exclusion Criteria:

          -  Gastric or duodenal ulcer verified by EGD within 12 weeks before randomisation.

          -  Use of any PPI from 14 days before EGD performed at the screening visit to the day of
             randomisation.